Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China

Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for
                  Development of siRNA Therapeutics in China

Invivofectamine® Rx-formulated therapeutic is 100-fold more potent than
previous in-vivo transfection products from Life

PR Newswire

CARLSBAD, Calif., June 19, 2013

CARLSBAD, Calif., June 19, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announces a licensing agreement granting Suzhou Ribo Life
Sciences (Ribo) the exclusive rights to develop and manufacture siRNA
therapeutics in China using Life's Invivofectamine® Rx delivery technology.
Ribo will formulate proprietary siRNA molecules in combination with
Invivofectamine® Rx to create a new platform designed to address human
diseases with high unmet medical need in the Chinese healthcare system.

Under the agreement, Ribo will receive a license to develop a robust pipeline
of Invivofectamine® Rx-based therapeutics, for each of which Life Technologies
is entitled to receive milestone and royalty payments.

Currently available only through Life Technologies' out-licensing program
(, Invivofectamine Rx marks a significant
advancement in the company's in vivo transfection product line. The novel
formulation uses a proprietary chemical structure to dramatically increase the
potency 100-fold and decrease the toxicity of the formulated RNAi compound.
The increased therapeutic window makes the solution particularly well-suited
for use in in vivo  applications.

"We are extremely pleased to announce this partnership with Life
Technologies," said Zicai Liang, Ph.D., chief executive officer and founder of
Ribo and the Kunshan RNAi Institute. "Adding Life's Invivofectamine Rx
formulation technology into our development efforts will significantly
increase our ability to bring new siRNA therapeutics to Chinese patients with
unmet medical needs. We look forward to bringing our first Invivofectamine
Rx-based program targeting Hepatitis-B into the clinic in a relatively short
period of time."

The Chinese government has identified siRNA therapeutics as one of the few
critical emerging technologies in which it wants to have a dominant presence.
To help meet this objective, the government is nearing completion on the
construction of a new, 400,000-square-foot, state-of-the-art facility in
Kunshan, China for Ribo Life Sciences and the Kunshan Institute of siRNA.

"Dr. Liang is a premier siRNA expert in China and his Kunshan RNAi Institute
is recognized as one of the world's leading consortiums of academic, industry
and government efforts in the world to advance siRNA technology," said Alan
Sachs, M.D., Ph.D., chief scientific officer and head of global research at
Life Technologies. "In our continued effort to deliver game-changing products
and technologies to the world's top medical researchers, we are pleased to
partner with Dr. Liang and Suzhou Ribo Life Sciences. Invivofectamine Rx is a
great example of the type of technology we will continue to license around the
world as we expand our commitment to clinical research customers."

About Suzhou Ribo Life Sciences

Suzhou Ribo Life Sciences Co. Ltd. (Ribo) was founded in 2007 and is located
in Kunshan, China. Ribo is devoted to the development of nucleic acid drugs
and other related products based on RNA interference (RNAi) technology. The
company was founded by Dr. Zicai Liang to partner with the Kunshan Institute
of siRNA in an effort to clinically advance RNAi therapeutics in China. With
China's biggest team of scientists and staff focused solely on RNAi research
and development, Ribo and its Kunshan RNAi Institute partnership represents
one of the world's leading efforts to develop RNAi therapeutics.

About Life Technologies

Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Life Technologies Contact
Mauricio Minotta

Suzhou Ribo Life Sciences Contact
Hongyan Zhang

SOURCE Life Technologies Corporation
Press spacebar to pause and continue. Press esc to stop.